NUVL
Price
$84.15
Change
-$0.49 (-0.58%)
Updated
Dec 20, 04:59 PM (EDT)
100 days until earnings call
RLAY
Price
$4.17
Change
-$0.09 (-2.11%)
Updated
Dec 20, 04:59 PM (EDT)
60 days until earnings call
Ad is loading...

NUVL vs RLAY

Header iconNUVL vs RLAY Comparison
Open Charts NUVL vs RLAYBanner chart's image
Nuvalent
Price$84.15
Change-$0.49 (-0.58%)
Volume$4.91K
CapitalizationN/A
Relay Therapeutics
Price$4.17
Change-$0.09 (-2.11%)
Volume$89.67K
CapitalizationN/A
NUVL vs RLAY Comparison Chart
Loading...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVL vs. RLAY commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and RLAY is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (NUVL: $84.22 vs. RLAY: $4.16)
Brand notoriety: NUVL and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 247% vs. RLAY: 317%
Market capitalization -- NUVL: $5.98B vs. RLAY: $697.15M
NUVL [@Biotechnology] is valued at $5.98B. RLAY’s [@Biotechnology] market capitalization is $697.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 4 TA indicator(s) are bullish while RLAY’s TA Score has 5 bullish TA indicator(s).

  • NUVL’s TA Score: 4 bullish, 4 bearish.
  • RLAY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RLAY is a better buy in the short-term than NUVL.

Price Growth

NUVL (@Biotechnology) experienced а -3.04% price change this week, while RLAY (@Biotechnology) price change was -11.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

NUVL is expected to report earnings on Apr 01, 2025.

RLAY is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.98B) has a higher market cap than RLAY($697M). NUVL YTD gains are higher at: 14.445 vs. RLAY (-62.216). NUVL has higher annual earnings (EBITDA): -240.51M vs. RLAY (-389.45M). NUVL has more cash in the bank: 1.17B vs. RLAY (840M). RLAY has higher revenues than NUVL: RLAY (10M) vs NUVL (0).
NUVLRLAYNUVL / RLAY
Capitalization5.98B697M858%
EBITDA-240.51M-389.45M62%
Gain YTD14.445-62.216-23%
P/E RatioN/AN/A-
Revenue010M-
Total Cash1.17B840M139%
Total DebtN/A49.8M-
TECHNICAL ANALYSIS
Technical Analysis
NUVLRLAY
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 14 days ago
80%
Declines
ODDS (%)
Bearish Trend 13 days ago
78%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 5 days ago
69%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WFOPX43.430.45
+1.05%
Allspring Opportunity C
JEQSX38.370.37
+0.97%
Johnson Equity Income S
JETTX15.370.13
+0.85%
Janus Henderson Global Sust Eq T
CBDYX52.230.36
+0.69%
Columbia Balanced Inst3
VGLSX10.190.05
+0.49%
VALIC Company I Global Strategy

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with ABCZF. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then ABCZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-0.50%
ABCZF - NUVL
51%
Loosely correlated
N/A
ASND - NUVL
41%
Loosely correlated
-0.99%
NCNA - NUVL
41%
Loosely correlated
N/A
IDYA - NUVL
39%
Loosely correlated
+3.31%
RLAY - NUVL
39%
Loosely correlated
-2.35%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with XNCR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
-2.35%
XNCR - RLAY
53%
Loosely correlated
+0.50%
ABOS - RLAY
45%
Loosely correlated
+2.78%
VCYT - RLAY
44%
Loosely correlated
+4.66%
TVTX - RLAY
44%
Loosely correlated
-1.26%
CCCC - RLAY
43%
Loosely correlated
+2.73%
More